IMPORTANCE: In asthma and other diseases, vitamin D insufficiency is associated with adverse outcomes. It is not known if supplementing inhaled corticosteroids with oral vitamin D3 improves outcomes in patients with asthma and vitamin D insufficiency. OBJECTIVE: To evaluate if vitamin D supplementation would improve the clinical efficacy of inhaled corticosteroids in patients with symptomatic asthma and lower vitamin D levels. DESIGN, SETTING, AND PARTICIPANTS: The VIDA (Vitamin D Add-on Therapy Enhances Corticosteroid Responsiveness in Asthma) randomized, double-blind, parallel, placebo-controlled trial studying adult patients with symptomatic asthma and a serum 25-hydroxyvitamin D level of less than 30 ng/mL was conducted across 9 academic US medical centers in the National Heart, Lung, and Blood Institute's AsthmaNet network, with enrollment starting in April 2011 and follow-up complete by January 2014. After a run-in period that included treatment with an inhaled corticosteroid, 408 patients were randomized. INTERVENTIONS:Oral vitamin D3 (100,000 IU once, then 4000 IU/d for 28 weeks; n = 201) or placebo (n = 207) was added to inhaled ciclesonide (320 µg/d). If asthma control was achieved after 12 weeks, ciclesonide was tapered to 160 µg/d for 8 weeks, then to 80 µg/d for 8 weeks if asthma control was maintained. MAIN OUTCOMES AND MEASURES: The primary outcome was time to first asthma treatment failure (a composite outcome of decline in lung function and increases in use of β-agonists, systemic corticosteroids, and health care). RESULTS: Treatment with vitamin D3 did not alter the rate of first treatment failure during 28 weeks (28% [95% CI, 21%-34%] with vitamin D3 vs 29% [95% CI, 23%-35%] with placebo; adjusted hazard ratio, 0.9 [95% CI, 0.6-1.3]). Of 14 prespecified secondary outcomes, 9 were analyzed, including asthma exacerbation; of those 9, the only statistically significant outcome was a small difference in the overall dose of ciclesonide required to maintain asthma control (111.3 µg/d [95% CI, 102.2-120.4 µg/d] in the vitamin D3 group vs 126.2 µg/d [95% CI, 117.2-135.3 µg/d] in the placebo group; difference of 14.9 µg/d [95% CI, 2.1-27.7 µg/d]). CONCLUSIONS AND RELEVANCE: Vitamin D3 did not reduce the rate of first treatment failure or exacerbation in adults with persistent asthma and vitamin D insufficiency. These findings do not support a strategy of therapeutic vitamin D3 supplementation in patients with symptomatic asthma. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01248065.
RCT Entities:
IMPORTANCE: In asthma and other diseases, vitamin Dinsufficiency is associated with adverse outcomes. It is not known if supplementing inhaled corticosteroids with oral vitamin D3 improves outcomes in patients with asthma and vitamin Dinsufficiency. OBJECTIVE: To evaluate if vitamin D supplementation would improve the clinical efficacy of inhaled corticosteroids in patients with symptomatic asthma and lower vitamin D levels. DESIGN, SETTING, AND PARTICIPANTS: The VIDA (Vitamin D Add-on Therapy Enhances Corticosteroid Responsiveness in Asthma) randomized, double-blind, parallel, placebo-controlled trial studying adult patients with symptomatic asthma and a serum 25-hydroxyvitamin D level of less than 30 ng/mL was conducted across 9 academic US medical centers in the National Heart, Lung, and Blood Institute's AsthmaNet network, with enrollment starting in April 2011 and follow-up complete by January 2014. After a run-in period that included treatment with an inhaled corticosteroid, 408 patients were randomized. INTERVENTIONS: Oral vitamin D3 (100,000 IU once, then 4000 IU/d for 28 weeks; n = 201) or placebo (n = 207) was added to inhaled ciclesonide (320 µg/d). If asthma control was achieved after 12 weeks, ciclesonide was tapered to 160 µg/d for 8 weeks, then to 80 µg/d for 8 weeks if asthma control was maintained. MAIN OUTCOMES AND MEASURES: The primary outcome was time to first asthma treatment failure (a composite outcome of decline in lung function and increases in use of β-agonists, systemic corticosteroids, and health care). RESULTS: Treatment with vitamin D3 did not alter the rate of first treatment failure during 28 weeks (28% [95% CI, 21%-34%] with vitamin D3 vs 29% [95% CI, 23%-35%] with placebo; adjusted hazard ratio, 0.9 [95% CI, 0.6-1.3]). Of 14 prespecified secondary outcomes, 9 were analyzed, including asthma exacerbation; of those 9, the only statistically significant outcome was a small difference in the overall dose of ciclesonide required to maintain asthma control (111.3 µg/d [95% CI, 102.2-120.4 µg/d] in the vitamin D3 group vs 126.2 µg/d [95% CI, 117.2-135.3 µg/d] in the placebo group; difference of 14.9 µg/d [95% CI, 2.1-27.7 µg/d]). CONCLUSIONS AND RELEVANCE: Vitamin D3 did not reduce the rate of first treatment failure or exacerbation in adults with persistent asthma and vitamin Dinsufficiency. These findings do not support a strategy of therapeutic vitamin D3 supplementation in patients with symptomatic asthma. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01248065.
Authors: Audrey H Poon; Catherine Laprise; Mathieu Lemire; Alexandre Montpetit; Donna Sinnett; Erwin Schurr; Thomas J Hudson Journal: Am J Respir Crit Care Med Date: 2004-07-28 Impact factor: 21.405
Authors: R F Lemanske; C A Sorkness; E A Mauger; S C Lazarus; H A Boushey; J V Fahy; J M Drazen; V M Chinchilli; T Craig; J E Fish; J G Ford; E Israel; M Kraft; R J Martin; S A Nachman; S P Peters; J D Spahn; S J Szefler Journal: JAMA Date: 2001 May 23-30 Impact factor: 56.272
Authors: S C Lazarus; H A Boushey; J V Fahy; V M Chinchilli; R F Lemanske; C A Sorkness; M Kraft; J E Fish; S P Peters; T Craig; J M Drazen; J G Ford; E Israel; R J Martin; E A Mauger; S A Nachman; J D Spahn; S J Szefler Journal: JAMA Date: 2001 May 23-30 Impact factor: 56.272
Authors: K Malmstrom; G Rodriguez-Gomez; J Guerra; C Villaran; A Piñeiro; L X Wei; B C Seidenberg; T F Reiss Journal: Ann Intern Med Date: 1999-03-16 Impact factor: 25.391
Authors: Stanley J Szefler; Brenda R Phillips; Fernando D Martinez; Vernon M Chinchilli; Robert F Lemanske; Robert C Strunk; Robert S Zeiger; Gary Larsen; Joseph D Spahn; Leonard B Bacharier; Gordon R Bloomberg; Theresa W Guilbert; Gregory Heldt; Wayne J Morgan; Mark H Moss; Christine A Sorkness; Lynn M Taussig Journal: J Allergy Clin Immunol Date: 2005-02 Impact factor: 10.793
Authors: Benjamin A Raby; Ross Lazarus; Edwin K Silverman; Steven Lake; Christoph Lange; Mathias Wjst; Scott T Weiss Journal: Am J Respir Crit Care Med Date: 2004-07-28 Impact factor: 21.405
Authors: Michael Schatz; Christine A Sorkness; James T Li; Philip Marcus; John J Murray; Robert A Nathan; Mark Kosinski; Trudy B Pendergraft; Priti Jhingran Journal: J Allergy Clin Immunol Date: 2006-03 Impact factor: 10.793
Authors: Emmanuel Xystrakis; Siddharth Kusumakar; Sandra Boswell; Emma Peek; Zoë Urry; David F Richards; Tonye Adikibi; Carol Pridgeon; Margaret Dallman; Tuck-Kay Loke; Douglas S Robinson; Franck J Barrat; Anne O'Garra; Paul Lavender; Tak H Lee; Christopher Corrigan; Catherine M Hawrylowicz Journal: J Clin Invest Date: 2005-12-08 Impact factor: 14.808
Authors: Ryan M Dunn; Erik Lehman; Vernon M Chinchilli; Richard J Martin; Homer A Boushey; Elliot Israel; Monica Kraft; Stephen C Lazarus; Robert F Lemanske; Njira L Lugogo; Stephen P Peters; Christine A Sorkness; Stanley Szefler; Michael E Wechsler Journal: Am J Respir Crit Care Med Date: 2015-09-01 Impact factor: 21.405
Authors: John J Lima; Mario Castro; Tonya S King; Jason E Lang; Victor E Ortega; Stephen P Peters; Loren C Denlinger; Elliot Israel; Christine A Sorkness; Michael E Wechsler; Sally E Wenzel; Lewis J Smith Journal: Ann Allergy Asthma Immunol Date: 2018-06-14 Impact factor: 6.347
Authors: Junfang Jiao; Tonya S King; Matthew McKenzie; Leonard B Bacharier; Anne E Dixon; Christopher D Codispoti; Ryan M Dunn; Nicole L Grossman; Njira L Lugogo; Sima K Ramratnam; Russell S Traister; Michael E Wechsler; Mario Castro Journal: J Allergy Clin Immunol Date: 2016-03-11 Impact factor: 10.793